The Cochrane review by Goldenberg et al. analyzed 31 randomized controlled trials (8,672 participants) examining probiotics for C. difficile-associated diarrhea. The pooled analysis showed a significant risk reduction (RR 0.40, 95% CI 0.30 to 0.52) for C. difficile-associated diarrhea when probiotics were co-administered with antibiotics. S. boulardii and L. rhamnosus GG were the most frequently studied strains with positive outcomes. The number needed to treat was 33 for moderate-risk populations and 12 for high-risk populations [1].
Allen et al. (2010) conducted a Cochrane meta-analysis of 63 trials covering 8,014 participants examining probiotics for acute infectious diarrhea. Probiotics reduced the mean duration of diarrhea by 24.76 hours (95% CI 15.9 to 33.6 hours). L. rhamnosus GG was the single most studied strain, and the effect was most pronounced in pediatric viral gastroenteritis. Doses exceeding 10 billion CFU per day appeared more effective than lower doses [2].
McFarland (2010) reviewed the evidence for Saccharomyces boulardii across multiple gastrointestinal indications. This probiotic yeast is notable because it is naturally resistant to antibiotics, making it particularly suitable for use during antibiotic therapy. The review found positive evidence for prevention of antibiotic-associated diarrhea (RR 0.47, 95% CI 0.35 to 0.63), traveler's diarrhea, and recurrent C. difficile infection. S. boulardii exerts its effects through multiple mechanisms including secretion of a protease that degrades C. difficile toxin A and stimulation of secretory IgA [3].
O'Mahony et al. (2005) conducted a randomized controlled trial comparing B. longum 35624, L. salivarius UCC4331, and placebo in IBS patients over 8 weeks. Only B. longum 35624 significantly reduced composite IBS symptom scores. Critically, this strain also normalized the IL-10/IL-12 cytokine ratio, which was abnormally skewed toward the pro-inflammatory IL-12 at baseline. This finding provided mechanistic evidence that certain probiotic strains can modulate systemic immune responses, not just local gut effects [5].
Francavilla et al. (2019) studied 109 celiac patients with persistent IBS-type symptoms despite adherence to a gluten-free diet. A 6-week course of a multispecies probiotic (containing Lactobacillus and Bifidobacterium strains) significantly reduced IBS Severity Scoring System scores and was associated with shifts in fecal microbiota composition, including increased Bifidobacterium counts. This study is notable because it demonstrates probiotic efficacy in a population where residual gut dysbiosis persists despite dietary treatment of the primary condition [4].